Ditchcarbon
  • Contact
  1. Organizations
  2. Pharmanutra
Public Profile
Pharmaceutical Preparation Manufacturing
IT
updated a month ago

Pharmanutra Sustainability Profile

Company website

Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.

DitchCarbon Score

How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

24

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Pharmanutra's score of 24 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

38%

Let us know if this data was useful to you

Pharmanutra's reported carbon emissions

In 2023, Pharmanutra reported total carbon emissions of approximately 1,151,014 kg CO2e. This figure includes 229,189 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources. Scope 2 emissions, primarily from purchased electricity, amounted to about 270,515 kg CO2e (market-based), while Scope 3 emissions, which include indirect emissions from business travel and employee commuting, totalled approximately 751,110 kg CO2e. Comparatively, in 2022, Pharmanutra's emissions were lower, with Scope 1 emissions at 199,150 kg CO2e and Scope 2 emissions at about 57,666 kg CO2e. The absence of Scope 3 data in 2022 indicates a significant increase in emissions reporting in 2023, particularly in the area of business travel, which accounted for 684,328 kg CO2e. Pharmanutra has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organisation, indicating that all reported figures are independently sourced from Pharmanutra S.p.A. Overall, Pharmanutra's commitment to addressing carbon emissions is evident through its comprehensive reporting, although further initiatives and targets would enhance its climate strategy.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2020202120222023
Scope 1
92,590
000,000
000,000
000,000
Scope 2
39.72
00,000
00,000
000,000
Scope 3
-
-
-
000,000

How Carbon Intensive is Pharmanutra's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Pharmanutra's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Pharmanutra's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Pharmanutra is in IT, which has a low grid carbon intensity relative to other regions.

Pharmanutra's Scope 3 Categories Breakdown

Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 61% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 89% of Scope 3 emissions.

Top Scope 3 Categories

2023
Business Travel
89%
Employee Commuting
11%

Pharmanutra's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Pharmanutra has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Pharmanutra's Emissions with Industry Peers

Chiesi Farmaceutici

IT
•
Pharmaceutical Preparation Manufacturing
Updated about 12 hours ago

Nature's Way

US
•
Health and social work services (85)
Updated 2 months ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Unilever

GB
•
Food products nec
Updated 1 day ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 14 hours ago

Procter And Gamble

US
•
Chemicals nec
Updated 3 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.5
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy